Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Precautions Needed for Infections in Treating RA with Actemra: PMS Data
December 15, 2008
- 2 Combinations of ARB and Diuretic Recommended for Approval
December 15, 2008
- Gov't to Relax Belt-Tightening Fiscal Policy
December 15, 2008
- REGULATORY NEWS IN BRIEF
December 15, 2008
- Research on Biomarkers Essential to Develop Anticancer Drugs: Dr Inoue
December 15, 2008
- Pfizer to Break Dependence on Blockbusters: Mr Iwasaki
December 15, 2008
- Tripartite Collaboration Needed to Bring Benefits of iPS Cells to Patients: Prof. Yamanaka
December 15, 2008
- Points to Remember in Developing Drugs for OAB Outlined by Former PMDA Reviewer
December 15, 2008
- Clarification of Diabetes-Related Genes Will Benefit Asians as a Whole
December 15, 2008
- PMDA to Create New Organization to Handle Int'l Affairs
December 15, 2008
- R&D NEWS IN BRIEF
December 15, 2008
- Korosho Starts Discussions on Distribution of Medical Devices
December 15, 2008
- Freedom from Fear in 2009
December 15, 2008
- PDA Closure Set from Japan Lifeline Recommended for Approval
December 15, 2008
- Chugai, Chiome Sign Agreement on Monoclonal Antibody Production
December 15, 2008
- SELF-MEDICATION NEWS IN BRIEF
December 15, 2008
- BUSINESS NEWS IN BRIEF
December 15, 2008
- SURVEY／Diabetes Is Most Commonly Examined
December 15, 2008
- Wholesalers Should Talk with Manufacturers on Equal Footing: Mr Negi
December 15, 2008
- JSMO to Prepare GL for KRAS Gene Mutation Testing
December 15, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…